Answers are grounded in this paper and cite their sources.
Radiomics is well placed to make clinically effective and cost-effective contributions to cancer care as a decision-making tool for personalised medicine. However, a systematic evaluative framework needs to be established so that these benefits can be demonstrated with confidence.
No takes yet. Share an insight, caveat, or question.
Kenneth A. Miles (2020) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: